Journal article
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
- Abstract:
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating enzyme of hepatic origin which plays a key role in low density lipoprotein (LDL) receptor turnover. Genetic studies have confirmed that those with gain-of-function PCSK9 mutations have increased PCSK9 activity, elevated LDLcholesterol levels and a severe form of familial hypercholesterolaemia, while those with variants leading to reduced PCSK9 have lower LDL-cholesterol and a reduced risk of coronary heart disease. This ha...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Springer Berlin Heidelberg Publisher's website
- Journal:
- Diabetologia Journal website
- Volume:
- 60
- Issue:
- 3
- Pages:
- 381–389
- Publication date:
- 2016-01-01
- Acceptance date:
- 2016-11-21
- DOI:
- EISSN:
-
1432-0428
- ISSN:
-
0012-186X
- Source identifiers:
-
660459
Item Description
- Keywords:
- Pubs id:
-
pubs:660459
- UUID:
-
uuid:457deba6-859b-45a4-b6f3-ea5fa8709576
- Local pid:
- pubs:660459
- Deposit date:
- 2016-11-21
Terms of use
- Copyright holder:
- Preiss and Mafham
- Copyright date:
- 2016
- Notes:
-
Copyright© 2016 The Authors.
Open Access
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record